Teplizumab, a new drug, could delay the need for insulin for patients with type 1 diabetes by up to 3 years.
Călin Nicolescu
Health
Foto Pixabay
Always see our news on Google
Teplizumab, a drug already approved in the US, is being tested in the UK to slow the progression of type 1 diabetes by training the immune system to protect pancreatic cells. Hannah Robinson, the first British adult to receive the treatment, hopes it will delay the need for insulin. Experts believe the treatment represents a major change in diabetes management, with the potential to alter the immune process and help high-risk people avoid insulin therapy.
Sources
Un medicament "revoluţionar" ar putea încetini evoluţia diabetului de tip 1. Poate întârzia nevoia de insulină cu 3 ani
Devon mother treated with game-changing diabetes drug
Mother of two becomes the first UK patient to receive ‘groundbreaking’ new diabetes drug
Un medicament „revoluționar”, o nouă speranță pentru diabetul de tip 1. Ce așteptări au medicii
Latest News
20:28
Latvia bans the import of goods from Russia and Belarus starting September 1
20:12
Cseke Attila announced that there is no incompatibility between local/county councilors and contractual staff in the administration, contrary to circulating information.
20:09
Drought and heat hit summer crops in the EU: corn decreases by 7%, soybeans by 14%, and fodder becomes a problem in the west and center of the continent.
19:59
Tirana, the most accessible urban destination in Europe. Bucharest ranks second.
19:53
MVM Energie Romania has received ANRE authorization for the development of a photovoltaic park in Covasna. The project will be carried out on 20 hectares.
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
